Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 286 to 300 of 456 results for chronic pain

  1. Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over (TA1003)

    Evidence-based recommendations on exagamglogene autotemcel (Casgevy) for transfusion-dependent beta-thalassaemia in people 12 years and over.

  2. Patient self-management plans:- What is the clinical and cost effectiveness of a self-management plan for people with stable angina?

    explanatory notes(if applicable) Why this is important:- Stable angina is a chronic condition. Evidence suggests that addressing...

  3. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (TA329)

    Evidence-based recommendations on infliximab (Remicade, Inflectra or Remsima), adalimumab (Humira) and golimumab (Simponi) for treating moderate to severe ulcerative colitis in adults, and on infliximab for treating severe active ulcerative colitis in children and young people of 6–17 years.

  4. Technology appraisal committee A members

    Biographies and registered interests for members of the Technology Appraisal Committee A

  5. Technology appraisal committee A members

    Biographies and registered interests for members of the Technology Appraisal Committee A

  6. Fertility problems: assessment and treatment (NG257)

    This guideline covers diagnosing and treating health-related fertility problems. It aims to reduce variation in practice and improve how fertility problems are investigated and managed.

  7. Parkinson's disease in adults (NG71)

    This guideline covers diagnosing and managing Parkinson's disease in people aged 18 and over. It aims to improve care from the time of diagnosis, including monitoring and managing symptoms, providing information and support, and palliative care.

  8. Pharmacological therapies:- What is the clinical and cost effectiveness of codeine with and without paracetamol for the acute management of low back pain?

    codeine with and without paracetamol for the acute management of low back pain? Any explanatory notes(if applicable) Why this is...

  9. Suspected sepsis in pregnant or recently pregnant people: recognition, diagnosis and early management (NG255)

    This guideline covers the recognition, diagnosis and early management of suspected sepsis in pregnant or recently pregnant people. It includes recommendations on recognition and early assessment, initial treatment, escalating care, finding and controlling the source of infection, early monitoring, information and support, and training and education.

  10. Idiopathic pulmonary fibrosis in adults (QS79)

    This quality standard covers managing idiopathic pulmonary fibrosis (gradual scarring of the lungs) in adults. It includes diagnosis by a multidisciplinary team, managing symptoms and palliative care. It describes high-quality care in priority areas for improvement.

  11. The Juxta CURES adjustable compression system for treating venous leg ulcers (MIB25)

    NICE has developed a medtech innovation briefing (MIB) on the Juxta CURES adjustable compression system for treating venous leg ulcers

  12. Obeticholic acid for treating primary biliary cholangitis (TA443)

    Evidence-based recommendations on obeticholic acid (Ocaliva) for treating primary biliary cholangitis in adults.

  13. Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis (TA624)

    Evidence-based recommendations on peginterferon beta-1a (Plegridy) for treating relapsing–remitting multiple sclerosis in adults.

  14. Prioritisation board decisions 2025

    Our centralised approach to prioritising our guidance topics ensures that we produce guidance that's relevant, timely, accessible, and has demonstrable impact.

  15. Tocilizumab for the treatment of systemic juvenile idiopathic arthritis (TA238)

    Evidence-based recommendations on tocilizumab (RoActemra), for treating systemic juvenile idiopathic arthritis in people aged 2 and over.